SUN-357 - Comparison Of Efficacy Of Liothyronine (T3) 50Mcg+Levothyroxine (T4) Combination Therapy Versus T4 Therapy Alone On Cardiac Markers In Patients With Hypothyroidism Followed For 6 Months

Aim: Compare the efficacy of Liothyronine (T3) 50mcg/d+Levothyroxine (T4) combination therapy versus T4 therapy alone on cardiac parameters {CP} (weight-kg [W], BMI-kg/m2, systolic BP (SBP-mm of Hg), Diastolic BP (DBP), Lipid Profile-mg/dl (TC, LDL, TG, HDL), highly sensitive C-reactive protein-mg/L (hs-CRP) & Thyrotropin stimulating hormone-mIU/L (TSH) evaluated every 2-3 mnths over 6 mnth period.

Methodology: Between Mar’ 24 - May ’24, 239 patients receiving T3 & T4 thyroid medication for autoimmune hypothyroidism were analysed retrospectively. They were divided into 2 groups & propensity score matched. Group 1: (G1) 50 pt’s received 50 mcg T3 + T4 therapy. Group 2: (G2) 189 pt’s received Only T4 therapy. Data Analysis: Baseline characteristics of G1 vs G2 groups were analysed using descriptive statistics. Categorical variables were described by frequencies and %, and continuous variables by using {mean ± SD}. Paired t test and unpaired t test was used to compare groups. P value < 0.05 was considered significant (S).

Results:
Baseline (B) characters: At baseline, G1 (n=50) and G2 (n=189) were well-matched including TSH. Average Age: [G1 (39.94 ± 9.45) vs. G2 (43.01 ± 10.52) years, p=0.183], except for: W [G1 (87.61 ± 19.13) vs. G2 (69.99 ± 13.82), p< 0.001], BMI [G1 (32.99 ± 7.81) vs. G2 (28.05 ± 5.12), p< 0.001], DBP [G1 (85.22 ± 9.03) vs. G2 (77.72 ± 9.60), p< 0.001].
G1 (B to 6months): S reduction in W, BMI, TSH, TC, LDL-C, hsCRP.
G2 (B to 6months): S reduction in SBP, TSH, TC, LDL-C, TG.

Differences between G1 & G2 at 6 months:
TSH [G1 (1.27 ± 1.40) Vs G2 (1.49 ± 1.40), p- 1.00)]. Significant reduction in Weight [G1 (2.63 ± 4.78 kg) vs. G2 (0.58 ± 6.00 kg); p = 0.020] & hsCRP [G1 (2.01 ± 4.37) vs. G2 (0.12 ± 2.75) mg/L; p < 0.001] favouring G1 was seen.

Conclusion: T3 (50 mcg) + T4 combination therapy significantly reduced body weight, hsCRP in comparison to only T4 therapy, while having no negative impact on blood pressure

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*